- Home
- JYD vs ASBP Comparison
JYD vs ASBP Comparison
Compare JYD & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JYD | ASBP |
|---|---|---|
| Founded | 2001 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.8M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | JYD | ASBP |
|---|---|---|
| Price | $0.77 | $5.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 346.9K | 245.5K |
| Earning Date | 05-15-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.05 |
| 52 Week High | $6.85 | $7.05 |
Technical Indicators
Market Signals| Indicator | JYD | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 29.70 | 61.55 |
| Support Level | $0.54 | $0.19 |
| Resistance Level | $1.07 | $6.98 |
| Average True Range (ATR) | 0.15 | 0.95 |
| MACD | 0.10 | -0.10 |
| Stochastic Oscillator | 16.09 | 83.86 |
Price Performance
Historical ComparisonAbout JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, fragmented logistics, and chartered airline freight services, supply chain management, and other value-added services.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.